http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 09 Jul 2026 08:00:26 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Century+Therapeutics+to+present+CNTY-813+preclinical+data+at+two+fall+congresses/26750392.html <p>Century Therapeutics (NASDAQ: IPSC) announced that preclinical data for its CNTY-813 program have been accepted for oral presentations at two scientific conferences scheduled for fall 2026, according to a company statement.</p> <p>The first presentation is scheduled for October 2, 2026, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy. Grant Welstead, PhD, Senior Vice President and Head of Research at Century Therapeutics, will present in a session focused on stem cell-to-beta cell therapy.</p> <p>The second presentation is set for October 9, 2026, at the Breakthrough T1D Clinical & Research Congress 2026 in Philadelphia, http://www.streetinsider.com/FDA/Century+Therapeutics+to+present+CNTY-813+preclinical+data+at+two+fall+congresses/26750392.html Thu, 09 Jul 2026 08:00:26 -0400 A.50215358 IPSC O.40693967 O.71462702 http://www.streetinsider.com/FDA/Century+Therapeutics+to+present+CNTY-813+preclinical+data+at+two+fall+congresses/26750392.html <p>Century Therapeutics (NASDAQ: IPSC) announced that preclinical data for its CNTY-813 program have been accepted for oral presentations at two scientific conferences scheduled for fall 2026, according to a company statement.</p> <p>The first presentation is scheduled for October 2, 2026, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy. Grant Welstead, PhD, Senior Vice President and Head of Research at Century Therapeutics, will present in a session focused on stem cell-to-beta cell therapy.</p> <p>The second presentation is set for October 9, 2026, at the Breakthrough T1D Clinical & Research Congress 2026 in Philadelphia, http://www.streetinsider.com/FDA/Century+Therapeutics+to+present+CNTY-813+preclinical+data+at+two+fall+congresses/26750392.html Thu, 09 Jul 2026 08:00:26 -0400 A.50215358 IPSC O.40693967 O.71462702 http://www.streetinsider.com/FDA/Century+Therapeutics+to+present+CNTY-813+preclinical+data+at+two+fall+congresses/26750392.html <p>Century Therapeutics (NASDAQ: IPSC) announced that preclinical data for its CNTY-813 program have been accepted for oral presentations at two scientific conferences scheduled for fall 2026, according to a company statement.</p> <p>The first presentation is scheduled for October 2, 2026, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy. Grant Welstead, PhD, Senior Vice President and Head of Research at Century Therapeutics, will present in a session focused on stem cell-to-beta cell therapy.</p> <p>The second presentation is set for October 9, 2026, at the Breakthrough T1D Clinical & Research Congress 2026 in Philadelphia, http://www.streetinsider.com/FDA/Century+Therapeutics+to+present+CNTY-813+preclinical+data+at+two+fall+congresses/26750392.html Thu, 09 Jul 2026 08:00:26 -0400 A.50215358 IPSC O.40693967 O.71462702 http://www.streetinsider.com/FDA/Century+Therapeutics+to+present+CNTY-813+preclinical+data+at+two+fall+congresses/26750392.html <p>Century Therapeutics (NASDAQ: IPSC) announced that preclinical data for its CNTY-813 program have been accepted for oral presentations at two scientific conferences scheduled for fall 2026, according to a company statement.</p> <p>The first presentation is scheduled for October 2, 2026, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy. Grant Welstead, PhD, Senior Vice President and Head of Research at Century Therapeutics, will present in a session focused on stem cell-to-beta cell therapy.</p> <p>The second presentation is set for October 9, 2026, at the Breakthrough T1D Clinical & Research Congress 2026 in Philadelphia, http://www.streetinsider.com/FDA/Century+Therapeutics+to+present+CNTY-813+preclinical+data+at+two+fall+congresses/26750392.html Thu, 09 Jul 2026 08:00:26 -0400 A.50215358 IPSC O.40693967 O.71462702 http://www.streetinsider.com/FDA/Century+Therapeutics+to+present+CNTY-813+preclinical+data+at+two+fall+congresses/26750369.html <p>Century Therapeutics (NASDAQ: IPSC) announced that preclinical data for its CNTY-813 program have been accepted for oral presentations at two scientific meetings scheduled for fall 2026, according to a company press release.</p> <p>The first presentation is scheduled for October 2, 2026, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy. Grant Welstead, PhD, Senior Vice President and Head of Research at Century Therapeutics, will present during a session focused on stem cell-to-beta cell therapy.</p> <p>The second presentation is set for October 9, 2026, at the Breakthrough T1D Clinical & Research Congress 2026 in http://www.streetinsider.com/FDA/Century+Therapeutics+to+present+CNTY-813+preclinical+data+at+two+fall+congresses/26750369.html Thu, 09 Jul 2026 08:00:18 -0400 IPSC http://www.streetinsider.com/Press+Releases/Century+Therapeutics+Selected+for+Oral+Presentations+of+CNTY-813+Preclinical+Data+at+EASD+2026+and+Breakthrough+T1D%C2%AE+Clinical+%26+Research+Congress+2026/26750304.html <p>PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced that its abstracts have been accepted for oral presentations at two upcoming scientific congresses:</p> <ul type="disc"><li style="margin-bottom:10pt;">62^nd Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 28–October 2, 2026 in Milan, Italy</li><li style="margin-bottom:10pt;">Breakthrough T1D^{<strong>®</strong>} Clinical &amp; Research Congress 2026 (CRC 2026), taking place October 9–11, 2026 in Philadelphia, Pennsylvania</li></ul> <p><br http://www.streetinsider.com/Press+Releases/Century+Therapeutics+Selected+for+Oral+Presentations+of+CNTY-813+Preclinical+Data+at+EASD+2026+and+Breakthrough+T1D%C2%AE+Clinical+%26+Research+Congress+2026/26750304.html Thu, 09 Jul 2026 08:00:00 -0400 IPSC http://www.streetinsider.com/Globe+Newswire/Century+Therapeutics+Selected+for+Oral+Presentations+of+CNTY-813+Preclinical+Data+at+EASD+2026+and+Breakthrough+T1D%C2%AE+Clinical+%26+Research+Congress+2026/26750304.html <p>PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced that its abstracts have been accepted for oral presentations at two upcoming scientific congresses:</p> <ul type="disc"><li style="margin-bottom:10pt;">62^nd Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 28–October 2, 2026 in Milan, Italy</li><li style="margin-bottom:10pt;">Breakthrough T1D^{<strong>®</strong>} Clinical &amp; Research Congress 2026 (CRC 2026), taking place October 9–11, 2026 in Philadelphia, Pennsylvania</li></ul> <p><br http://www.streetinsider.com/Globe+Newswire/Century+Therapeutics+Selected+for+Oral+Presentations+of+CNTY-813+Preclinical+Data+at+EASD+2026+and+Breakthrough+T1D%C2%AE+Clinical+%26+Research+Congress+2026/26750304.html Thu, 09 Jul 2026 08:00:00 -0400 IPSC http://www.streetinsider.com/Press+Releases/Century+Therapeutics+Selected+for+Oral+Presentations+of+CNTY-813+Preclinical+Data+at+EASD+2026+and+Breakthrough+T1D%C2%AE+Clinical+%26amp%3B+Research+Congress+2026/26750345.html <p>PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced that its abstracts have been accepted for oral presentations at two upcoming scientific congresses:</p> <ul type="disc"><li style="margin-bottom:10pt;">62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 28–October 2, 2026 in Milan, Italy</li><li style="margin-bottom:10pt;">Breakthrough T1D<strong>®</strong> Clinical &amp; Research Congress 2026 (CRC 2026), taking place October 9–11, 2026 in Philadelphia, Pennsylvania</li></ul> <p><br/>Both http://www.streetinsider.com/Press+Releases/Century+Therapeutics+Selected+for+Oral+Presentations+of+CNTY-813+Preclinical+Data+at+EASD+2026+and+Breakthrough+T1D%C2%AE+Clinical+%26amp%3B+Research+Congress+2026/26750345.html Thu, 09 Jul 2026 08:00:00 -0400 A.50215358 IPSC O.40693967 O.71462702 http://www.streetinsider.com/Press+Releases/Century+Therapeutics+Selected+for+Oral+Presentations+of+CNTY-813+Preclinical+Data+at+EASD+2026+and+Breakthrough+T1D%C2%AE+Clinical+%26amp%3B+Research+Congress+2026/26750345.html <p>PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced that its abstracts have been accepted for oral presentations at two upcoming scientific congresses:</p> <ul type="disc"><li style="margin-bottom:10pt;">62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 28–October 2, 2026 in Milan, Italy</li><li style="margin-bottom:10pt;">Breakthrough T1D<strong>®</strong> Clinical &amp; Research Congress 2026 (CRC 2026), taking place October 9–11, 2026 in Philadelphia, Pennsylvania</li></ul> <p><br/>Both http://www.streetinsider.com/Press+Releases/Century+Therapeutics+Selected+for+Oral+Presentations+of+CNTY-813+Preclinical+Data+at+EASD+2026+and+Breakthrough+T1D%C2%AE+Clinical+%26amp%3B+Research+Congress+2026/26750345.html Thu, 09 Jul 2026 08:00:00 -0400 A.50215358 IPSC O.40693967 O.71462702 http://www.streetinsider.com/Press+Releases/Century+Therapeutics+Selected+for+Oral+Presentations+of+CNTY-813+Preclinical+Data+at+EASD+2026+and+Breakthrough+T1D%C2%AE+Clinical+%26amp%3B+Research+Congress+2026/26750345.html <p>PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced that its abstracts have been accepted for oral presentations at two upcoming scientific congresses:</p> <ul type="disc"><li style="margin-bottom:10pt;">62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 28–October 2, 2026 in Milan, Italy</li><li style="margin-bottom:10pt;">Breakthrough T1D<strong>®</strong> Clinical &amp; Research Congress 2026 (CRC 2026), taking place October 9–11, 2026 in Philadelphia, Pennsylvania</li></ul> <p><br/>Both http://www.streetinsider.com/Press+Releases/Century+Therapeutics+Selected+for+Oral+Presentations+of+CNTY-813+Preclinical+Data+at+EASD+2026+and+Breakthrough+T1D%C2%AE+Clinical+%26amp%3B+Research+Congress+2026/26750345.html Thu, 09 Jul 2026 08:00:00 -0400 A.50215358 IPSC O.40693967 O.71462702 http://www.streetinsider.com/Press+Releases/Century+Therapeutics+Selected+for+Oral+Presentations+of+CNTY-813+Preclinical+Data+at+EASD+2026+and+Breakthrough+T1D%C2%AE+Clinical+%26amp%3B+Research+Congress+2026/26750345.html <p>PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced that its abstracts have been accepted for oral presentations at two upcoming scientific congresses:</p> <ul type="disc"><li style="margin-bottom:10pt;">62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 28–October 2, 2026 in Milan, Italy</li><li style="margin-bottom:10pt;">Breakthrough T1D<strong>®</strong> Clinical &amp; Research Congress 2026 (CRC 2026), taking place October 9–11, 2026 in Philadelphia, Pennsylvania</li></ul> <p><br/>Both http://www.streetinsider.com/Press+Releases/Century+Therapeutics+Selected+for+Oral+Presentations+of+CNTY-813+Preclinical+Data+at+EASD+2026+and+Breakthrough+T1D%C2%AE+Clinical+%26amp%3B+Research+Congress+2026/26750345.html Thu, 09 Jul 2026 08:00:00 -0400 A.50215358 IPSC O.40693967 O.71462702 http://www.streetinsider.com/Globe+Newswire/Century+Therapeutics+Selected+for+Oral+Presentations+of+CNTY-813+Preclinical+Data+at+EASD+2026+and+Breakthrough+T1D%C2%AE+Clinical+%26amp%3B+Research+Congress+2026/26750345.html <p>PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced that its abstracts have been accepted for oral presentations at two upcoming scientific congresses:</p> <ul type="disc"><li style="margin-bottom:10pt;">62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 28–October 2, 2026 in Milan, Italy</li><li style="margin-bottom:10pt;">Breakthrough T1D<strong>®</strong> Clinical &amp; Research Congress 2026 (CRC 2026), taking place October 9–11, 2026 in Philadelphia, Pennsylvania</li></ul> <p><br/>Both http://www.streetinsider.com/Globe+Newswire/Century+Therapeutics+Selected+for+Oral+Presentations+of+CNTY-813+Preclinical+Data+at+EASD+2026+and+Breakthrough+T1D%C2%AE+Clinical+%26amp%3B+Research+Congress+2026/26750345.html Thu, 09 Jul 2026 08:00:00 -0400 A.50215358 IPSC O.40693967 O.71462702 http://www.streetinsider.com/Globe+Newswire/Century+Therapeutics+Selected+for+Oral+Presentations+of+CNTY-813+Preclinical+Data+at+EASD+2026+and+Breakthrough+T1D%C2%AE+Clinical+%26amp%3B+Research+Congress+2026/26750345.html <p>PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced that its abstracts have been accepted for oral presentations at two upcoming scientific congresses:</p> <ul type="disc"><li style="margin-bottom:10pt;">62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 28–October 2, 2026 in Milan, Italy</li><li style="margin-bottom:10pt;">Breakthrough T1D<strong>®</strong> Clinical &amp; Research Congress 2026 (CRC 2026), taking place October 9–11, 2026 in Philadelphia, Pennsylvania</li></ul> <p><br/>Both http://www.streetinsider.com/Globe+Newswire/Century+Therapeutics+Selected+for+Oral+Presentations+of+CNTY-813+Preclinical+Data+at+EASD+2026+and+Breakthrough+T1D%C2%AE+Clinical+%26amp%3B+Research+Congress+2026/26750345.html Thu, 09 Jul 2026 08:00:00 -0400 A.50215358 IPSC O.40693967 O.71462702 http://www.streetinsider.com/Globe+Newswire/Century+Therapeutics+Selected+for+Oral+Presentations+of+CNTY-813+Preclinical+Data+at+EASD+2026+and+Breakthrough+T1D%C2%AE+Clinical+%26amp%3B+Research+Congress+2026/26750345.html <p>PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced that its abstracts have been accepted for oral presentations at two upcoming scientific congresses:</p> <ul type="disc"><li style="margin-bottom:10pt;">62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 28–October 2, 2026 in Milan, Italy</li><li style="margin-bottom:10pt;">Breakthrough T1D<strong>®</strong> Clinical &amp; Research Congress 2026 (CRC 2026), taking place October 9–11, 2026 in Philadelphia, Pennsylvania</li></ul> <p><br/>Both http://www.streetinsider.com/Globe+Newswire/Century+Therapeutics+Selected+for+Oral+Presentations+of+CNTY-813+Preclinical+Data+at+EASD+2026+and+Breakthrough+T1D%C2%AE+Clinical+%26amp%3B+Research+Congress+2026/26750345.html Thu, 09 Jul 2026 08:00:00 -0400 A.50215358 IPSC O.40693967 O.71462702 http://www.streetinsider.com/Globe+Newswire/Century+Therapeutics+Selected+for+Oral+Presentations+of+CNTY-813+Preclinical+Data+at+EASD+2026+and+Breakthrough+T1D%C2%AE+Clinical+%26amp%3B+Research+Congress+2026/26750345.html <p>PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced that its abstracts have been accepted for oral presentations at two upcoming scientific congresses:</p> <ul type="disc"><li style="margin-bottom:10pt;">62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 28–October 2, 2026 in Milan, Italy</li><li style="margin-bottom:10pt;">Breakthrough T1D<strong>®</strong> Clinical &amp; Research Congress 2026 (CRC 2026), taking place October 9–11, 2026 in Philadelphia, Pennsylvania</li></ul> <p><br/>Both http://www.streetinsider.com/Globe+Newswire/Century+Therapeutics+Selected+for+Oral+Presentations+of+CNTY-813+Preclinical+Data+at+EASD+2026+and+Breakthrough+T1D%C2%AE+Clinical+%26amp%3B+Research+Congress+2026/26750345.html Thu, 09 Jul 2026 08:00:00 -0400 A.50215358 IPSC O.40693967 O.71462702 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Century+Therapeutics%2C+++++For%3A+Jun+15/26654092.html si-local-file:///var/storage/secattach/20260616/26654092.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Century+Therapeutics%2C+++++For%3A+Jun+15/26654092.html Tue, 16 Jun 2026 16:07:00 -0400 IPSC O.40693967 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Century+Therapeutics%2C+++++For%3A+Jun+15/26654092.html si-local-file:///var/storage/secattach/20260616/26654092.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Century+Therapeutics%2C+++++For%3A+Jun+15/26654092.html Tue, 16 Jun 2026 16:07:00 -0400 IPSC O.40693967 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Century+Therapeutics%2C+++++For%3A+Jun+12++Filed+by%3A+Russotti+Gregory/26649078.html si-local-file:///var/storage/secattach/20260615/26649078.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Century+Therapeutics%2C+++++For%3A+Jun+12++Filed+by%3A+Russotti+Gregory/26649078.html Mon, 15 Jun 2026 19:58:00 -0400 IPSC O.40693967 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Century+Therapeutics%2C+++++For%3A+Jun+12++Filed+by%3A+Russotti+Gregory/26649078.html si-local-file:///var/storage/secattach/20260615/26649078.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Century+Therapeutics%2C+++++For%3A+Jun+12++Filed+by%3A+Russotti+Gregory/26649078.html Mon, 15 Jun 2026 19:58:00 -0400 IPSC O.40693967 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Century+Therapeutics%2C+++++For%3A+Jun+11++Filed+by%3A+Pfeiffenberger+Brent/26649071.html si-local-file:///var/storage/secattach/20260615/26649071.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Century+Therapeutics%2C+++++For%3A+Jun+11++Filed+by%3A+Pfeiffenberger+Brent/26649071.html Mon, 15 Jun 2026 19:56:00 -0400 IPSC O.40693967 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Century+Therapeutics%2C+++++For%3A+Jun+11++Filed+by%3A+Pfeiffenberger+Brent/26649071.html si-local-file:///var/storage/secattach/20260615/26649071.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Century+Therapeutics%2C+++++For%3A+Jun+11++Filed+by%3A+Pfeiffenberger+Brent/26649071.html Mon, 15 Jun 2026 19:56:00 -0400 IPSC O.40693967 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Century+Therapeutics%2C+++++For%3A+Jun+12++Filed+by%3A+Carr+Douglas/26649072.html si-local-file:///var/storage/secattach/20260615/26649072.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Century+Therapeutics%2C+++++For%3A+Jun+12++Filed+by%3A+Carr+Douglas/26649072.html Mon, 15 Jun 2026 19:56:00 -0400 IPSC O.40693967 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Century+Therapeutics%2C+++++For%3A+Jun+12++Filed+by%3A+Carr+Douglas/26649072.html si-local-file:///var/storage/secattach/20260615/26649072.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Century+Therapeutics%2C+++++For%3A+Jun+12++Filed+by%3A+Carr+Douglas/26649072.html Mon, 15 Jun 2026 19:56:00 -0400 IPSC O.40693967 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Century+Therapeutics%2C+++++For%3A+Jun+11++Filed+by%3A+Cowan+Chad/26649068.html si-local-file:///var/storage/secattach/20260615/26649068.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Century+Therapeutics%2C+++++For%3A+Jun+11++Filed+by%3A+Cowan+Chad/26649068.html Mon, 15 Jun 2026 19:54:00 -0400 IPSC O.40693967 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Century+Therapeutics%2C+++++For%3A+Jun+11++Filed+by%3A+Cowan+Chad/26649068.html si-local-file:///var/storage/secattach/20260615/26649068.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Century+Therapeutics%2C+++++For%3A+Jun+11++Filed+by%3A+Cowan+Chad/26649068.html Mon, 15 Jun 2026 19:54:00 -0400 IPSC O.40693967